4 trends with the potential to change behavior in the patient journey

It's a common refrain in healthcare and among patients, providers, and payers: Despite massive investment, no one has figured out how to change human behavior.

Competition may threaten Gilead as market leader

Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.

J&J taps Sneed as communications chief

J&J taps Sneed as communications chief

Johnson & Johnson has appointed Michael Sneed, its worldwide VP of global corporate affairs, to the additional role of chief communications officer.

Five things for pharma marketers to know: Monday, May 23, 2016

Five things for pharma marketers to know: Monday, May 23, 2016

E.U. lifts warning on Pfizer's Chantix; Obama's Medicare Part B proposal panned by lawmakers; France to propose stricter rules for clinical trials

Top 25 infectious disease products in 2015

Top 25 infectious disease products in 2015

To no surprise, Gilead Sciences' Harvoni and Sovaldi were the top-selling infectious disease products in 2015.

Drugmakers renew interest in antibiotic development

Drugmakers renew interest in antibiotic development

The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.

W2O sells stake to private-equity firm

W2O sells stake to private-equity firm

The agency network said the private equity firm won't be involved in its day-to-day operations, but it will help its growth strategy.

Five things for pharma marketers to know: Friday, May 20, 2016

Five things for pharma marketers to know: Friday, May 20, 2016

Keytruda's survival benefit is reinforced by new study; drugmakers reference patient-assistance programs in debate over drug prices; China cuts drug prices

Blue Cross Blue Shield RI on introducing email segmentation

Blue Cross Blue Shield RI on introducing email segmentation

Health insurance provider Blue Cross Blue Shield Rhode Island drove engagement, leads, and conversion through its segmented campaigns.

Five things for pharma marketers to know: Thursday, May 19, 2016

Five things for pharma marketers to know: Thursday, May 19, 2016

Novartis plans new trials for Entresto; U.S. spending on mental health topped $201 billion in 2013; the FDA approves Roche's immunotherapy drug

Industry criticizes FDA's proposed DTC studies

Industry criticizes FDA's proposed DTC studies

Pharma companies took issue with the methodology for the FDA's proposed studies of advertising tactics.

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

BodenPR helps UnitedHealthcare educate Hispanic seniors about Medicare

UnitedHealthcare this month launched a year-long campaign, called Hay Más Adelante.

Five things for pharma marketers to know: Wednesday, May 18, 2016

Five things for pharma marketers to know: Wednesday, May 18, 2016

Opdivo nets new indication; government to view Humira patent; AstraZeneca's asthma drug expected to be filed this year

The Medicines Company appoints former Biogen exec to lead commercial activities

The Medicines Company appoints former Biogen exec to lead commercial activities

Tony Kingsley will oversee the company's daily operations and commercial activities.

Novartis splits pharma division, shakes up management team

Novartis splits pharma division, shakes up management team

Novartis breaks up pharmaceutical division and announces that David Epstein, CEO of Novartis Pharmaceuticals, will leave the company.

Ponemon: Cybercrime is top cause for healthcare data breaches

Ponemon: Cybercrime is top cause for healthcare data breaches

A 69% majority of healthcare organizations said they believe their industry is more vulnerable to data breaches than other business sectors.

Agency Spotlight


OPINION

Email Newsletters